Cellzome, Inc. and GlaxoSmithKline entered a worldwide strategic alliance to discover, develop and market novel kinase-targeted therapeutics to treat inflammatory diseases. The alliance gives GSK access to Cellzome’s expertise in identifying and developing selective kinase inhibitors and its Kinobeads technology, which screens compounds in a physiological setting and is designed to improve the predictability of these drug candidates in clinical testing. Kinases are key molecular switches i...